

Nadine Beha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6886458/publications.pdf>

Version: 2024-02-01

12
papers

131
citations

1478505

6
h-index

1281871

11
g-index

12
all docs

12
docs citations

12
times ranked

150
citing authors

#	ARTICLE	IF	CITATIONS
1	Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc). <i>Oncolmunology</i> , 2022, 11, 2028961.	4.6	3
2	The elg technology to generate Ig-like bispecific antibodies. <i>MAbs</i> , 2022, 14, 2063043.	5.2	4
3	A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3. <i>MAbs</i> , 2021, 13, 1902034.	5.2	6
4	A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells. <i>Scientific Reports</i> , 2021, 11, 13880.	3.3	6
5	Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release. , 2021, 9, e003616.		4
6	Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1474-1485.	4.1	27
7	Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2291-2303.	4.2	5
8	IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1278-1288.	4.1	12
9	Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules. <i>MAbs</i> , 2019, 11, 919-929.	5.2	19
10	Production, Purification, and Characterization of Antibody-TNF Superfamily Ligand Fusion Proteins. <i>Methods in Molecular Biology</i> , 2018, 1827, 351-364.	0.9	2
11	Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors. <i>Oncolmunology</i> , 2017, 6, e1361594.	4.6	10
12	Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format. <i>Oncolmunology</i> , 2016, 5, e1238540.	4.6	33